We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Nabi’s Outlook Poor as Key Drug Misses Phase III Endpoint
Nabi’s Outlook Poor as Key Drug Misses Phase III Endpoint
July 22, 2011
Patients treated with smoking cessation vaccine NicVAX failed to quit smoking at higher rates than those treated with a placebo in a Phase III trial, signaling bad news for drug developer Nabi Biopharmaceuticals.